Investigational agent improves interstitial cystitis pain
An investigational bladder instillation appears to improve daytime pain in patients with painful bladder syndrome/interstitial cystitis in a single dose, according to interim results of a phase II study.
An investigational bladder instillation appears to improve daytime pain in patients with painful bladder syndrome/interstitial cystitis in a single dose, according to interim results of a phase II study.
The multicenter, double-blind, crossover study compared URG101, a lidocaine and heparin solution, with placebo in 21 patients.
URG101 was significantly better than placebo in the primary efficacy measurement of improvement in daytime pain (p=.03). The drug also fared better than placebo in the secondary endpoints of improvement in daytime urgency (p=.03) and total symptom score (p=.03). In addition, patients reported improved symptom relief with the pharmaceutical treatment as measured by patients’ overall ratings of improvements of symptoms (p=.01), according to Urigen Pharmaceuticals, the drug’s manufacturer.
Additional analyses are ongoing. Results will be used to gauge whether additional patients will be enrolled in the study, which is designed for 50 subjects.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.
